KR20220168036A - Skin external application composition for improving seborrheic dematitis - Google Patents
Skin external application composition for improving seborrheic dematitis Download PDFInfo
- Publication number
- KR20220168036A KR20220168036A KR1020210077546A KR20210077546A KR20220168036A KR 20220168036 A KR20220168036 A KR 20220168036A KR 1020210077546 A KR1020210077546 A KR 1020210077546A KR 20210077546 A KR20210077546 A KR 20210077546A KR 20220168036 A KR20220168036 A KR 20220168036A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- external application
- extract
- seborrheic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 239000000284 extract Substances 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 241000722195 Potamogeton Species 0.000 claims abstract description 5
- 210000004761 scalp Anatomy 0.000 claims description 38
- 206010036790 Productive cough Diseases 0.000 claims description 34
- 208000024794 sputum Diseases 0.000 claims description 34
- 210000003802 sputum Anatomy 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 210000002374 sebum Anatomy 0.000 claims description 27
- 206010061218 Inflammation Diseases 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 230000004054 inflammatory process Effects 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001291474 Malassezia globosa Species 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 231100000676 disease causative agent Toxicity 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 241001291477 Malassezia restricta Species 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 102000004882 Lipase Human genes 0.000 claims description 8
- 108090001060 Lipase Proteins 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 208000026435 phlegm Diseases 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 235000015961 tonic Nutrition 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 229960000716 tonics Drugs 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 10
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 210000001732 sebaceous gland Anatomy 0.000 description 11
- -1 tracanth Substances 0.000 description 11
- 241000555676 Malassezia Species 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000004378 sebocyte Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YNGNVZFHHJEZKD-UHFFFAOYSA-N (4-nitrophenyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 YNGNVZFHHJEZKD-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- AQUCOCCZWYJKFZ-UHFFFAOYSA-M diethyl(dioctadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CCCCCCCCCCCCCCCCCC AQUCOCCZWYJKFZ-UHFFFAOYSA-M 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000003652 hormone inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 가래 추출물을 유효성분으로 함유하는 지루성 피부염 개선용 조성물에 관한 것이다. The present invention relates to a composition for improving seborrheic dermatitis containing a sputum extract as an active ingredient.
피부 피지선은 피지로 알려진 지질의 혼합물을 분비하는 완전 분비선이다. “피지”라는 용어는 트리글리세라이드, 유리 지방산, 왁스 에스테르, 스쿠알렌, 콜레스테롤 및 콜레스테릴 에스테르를 포함하는 피지선의 분비물을 가리킨다. 피지선에서 피지가 과다 생성되면 지성피부가 나타나게 되고, 또한, 여드름 및 지루성 피부염 등 다른 피부장애, 질환 또는 상태의 발현 원인이 될 수 있다. 피지의 생성은 피지선 세포의 증식과 분화에 영향을 미치는 인자들에 의하여 조절되며, 남성호르몬, 여성호르몬, IGF-1(insulin-like growth factor), PPAR(peroxisome proliferatoractivated receptor)과 같은 인자들이 피지생성에 관련된 것으로 알려져 있다. 피지선 세포에 의해서 생성된 피지는 모낭관을 거쳐 피부 표면으로 분비되고, 생성된 피지는 피부 표면에서 각질 세포간 지질의 구조를 변화시켜 피부 장벽 기능을 저하시키는 것으로 알려져 있으며, 피지의 과다 생성으로 인한 지루성 두피염균 등의 과증식이 지루성 피부염 및 두피염의 원인으로 알려져 있다. 따라서, 생성된 피지의 적절한 제거와 피지생성 억제가 피부장벽 기능과 건강한 피부의 유지를 위하여 중요하게 여겨지고 있다.Skin sebaceous glands are fully secreted glands that secrete a mixture of lipids known as sebum. The term "sebum" refers to the secretion of the sebaceous glands containing triglycerides, free fatty acids, wax esters, squalene, cholesterol and cholesteryl esters. Excessive production of sebum in the sebaceous glands results in oily skin and can also contribute to the development of other skin disorders, diseases or conditions, such as acne and seborrheic dermatitis. Sebum production is regulated by factors that affect the proliferation and differentiation of sebaceous gland cells, and factors such as male hormones, female hormones, IGF-1 (insulin-like growth factor), and PPAR (peroxisome proliferator activated receptor) are involved in sebum production. known to be related to Sebum produced by sebaceous gland cells is secreted to the skin surface through the hair follicle duct, and the produced sebum is known to degrade the skin barrier function by changing the structure of lipids between keratinocytes on the skin surface. Overgrowth of seborrheic scalpitis bacteria is known to be the cause of seborrheic dermatitis and scalpitis. Therefore, proper removal of the produced sebum and suppression of sebum production are considered important for maintaining the skin barrier function and healthy skin.
피지생성 억제를 위한 방법으로 남성 호르몬인 테스토스테론(testosterone)을 디하이드로테스토스테론(dihydrotestosterone)으로 변환시키는 기능을 하는 5-알파리덕타제(5α-reductase)를 저해하는 물질이 개발되어 사용되고 있다. 또한 테스토스테론과 디하이드로테스토스테론의 수용체와의 결합을 저해하는 안드로겐 리셉터 저해제(anti-androgen receptor)를 경피 적용하여 피지생성을 억제하기 위한 노력이 진행되고 있다. 그러나, 이러한 호르몬 억제제들은 경피 전달에 어려움이 있으며, 경피 투여로 효과적으로 전달이 되어도 전신의 호르몬 균형에 영향을 줄 수 있을 가능성이 있어 개발이 용이하지 않은 단점이 있다.As a method for suppressing sebum production, a substance that inhibits 5α-reductase, which functions to convert testosterone, a male hormone, into dihydrotestosterone, has been developed and used. In addition, efforts are being made to inhibit sebum production by transdermal application of an androgen receptor inhibitor that inhibits the binding of testosterone and dihydrotestosterone to the receptor. However, these hormone inhibitors have difficulties in transdermal delivery, and even if they are effectively delivered by transdermal administration, there is a possibility that they may affect the balance of hormones throughout the body, so development is not easy.
한편, 지루성 피부염은 10명중 3명꼴로 일어나는 매우 흔한 질병으로 얼굴뿐만 아니라 두피에도 증상이 자주 발생하는데 이처럼 두피에 발생하는 것을 지루성 두피염이라 한다.On the other hand, seborrheic dermatitis is a very common disease that occurs in 3 out of 10 people, and symptoms often occur not only on the face but also on the scalp.
본 발명의 목적은 인체에 해가 없는 천연물질로 구성된 지루성 피부염을 개선할 수 있는 피부외용제 조성물을 제공하는 것이다.An object of the present invention is to provide a composition for external application for skin that can improve seborrheic dermatitis composed of natural substances harmless to the human body.
본 발명의 목적을 달성하기 위하여 본 발명은 가래(Potamogeton distincutus) 추출물을 유효성분으로 함유하는 지루성 피부 염증 개선용 피부 외용제 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a composition for topical skin application for improving seborrheic skin inflammation containing an extract of Potamogeton distincutus as an active ingredient.
일 실시예에 의하면, 상기 피부가 두피인 것이 바람직하다.According to one embodiment, it is preferable that the skin is the scalp.
일 실시예에 의하면, 상기 가래 추출물의 함량은 조성물 총 중량에 대하여 0.001~10 중량%로 포함되는 것이 바람직하다.According to one embodiment, the content of the sputum extract is preferably included in 0.001 to 10% by weight based on the total weight of the composition.
일 실시예에 의하면, 상기 조성물은 지루성 두피 염증 원인균에 의한 피지 과다 생성을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다.According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by suppressing excessive production of sebum by the causative agent of seborrheic scalp inflammation.
일 실시예에 의하면, 상기 조성물은 지루성 두피 염증 원인균에 의한 염증성 사이토카인 발현 촉진을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다.According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by suppressing the promotion of inflammatory cytokine expression by the causative bacteria of seborrheic scalp inflammation.
일 실시예에 의하면, 상기 조성물은 지루성 두피 염증 원인균의 리파아제 효소 활성을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다.According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by inhibiting the lipase enzyme activity of the causative agent of seborrheic scalp inflammation.
일 실시예에 의하면, 상기 지루성 두피 염증 원인균은 Malassezia globosa와 Malassezia restricta인 것이 바람직하다.According to one embodiment, the causative bacteria of seborrheic scalp inflammation are preferably Malassezia globosa and Malassezia restricta .
일 실시예에 의하면, 상기 추출물은 물, 유기 용매 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상의 추출물인 것이 바람직하다.According to one embodiment, the extract is preferably one or more extracts selected from the group consisting of water, organic solvents, and mixtures thereof.
상기 추출물은 가래를 잘 씻어 건조한 뒤, 물, 유기용매 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상의 추출물인 것이 바람직하다. 상기 유기용매는 탄소수 1 내지 10의 무수 또는 함유 메탄올, 에탄올, 프로필알코올, 부틸알코올, 글리세린, 프로필렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 1종 이상일 수 있다.The extract is preferably one or more extracts selected from the group consisting of water, organic solvents, and mixtures thereof after washing and drying the sputum well. The organic solvent may be at least one selected from the group consisting of methanol, ethanol, propyl alcohol, butyl alcohol, glycerin, propylene glycol, and butylene glycol having 1 to 10 carbon atoms.
일 실시예에 의하면, 상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 로션, 파우더, 비누, 계면활성제 함유 클린싱 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 샴푸, 린스, 토닉 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것이 바람직하다.According to one embodiment, the composition is a group consisting of solutions, suspensions, emulsions, pastes, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations, shampoos, rinses, tonics and sprays It is preferred to have a formulation selected from
일 실시예에 의하면, 상기 피부 외용제 조성물이 두피 상태 개선용 화장료 조성물인 것이 바람직하다.According to one embodiment, it is preferable that the composition for external application for skin is a cosmetic composition for improving scalp condition.
일 실시예에 의하면, 상기 피부 외용제 조성물이 두피 상태 개선용 의약외품 조성물인 것이 바람직하다.According to one embodiment, it is preferable that the composition for external application for skin is a quasi-drug composition for improving scalp conditions.
본 발명에 따른 조성물은 지루성 피부 염증 원인균에 의한 피지 과다 생성을 억제하는 효과가 있다.The composition according to the present invention has an effect of suppressing excessive production of sebum caused by a causative agent of seborrheic skin inflammation.
본 발명에 따른 조성물은 지루성 피부 원인균에 의한 염증성 사이토카인 발현을 억제하는 효과가 있다.The composition according to the present invention has an effect of inhibiting the expression of inflammatory cytokines caused by seborrheic skin causative bacteria.
본 발명에 따른 조성물은 지루성 피부 염증 원인균의 리파아제 효소 활성을 저해하는 효과가 있다.The composition according to the present invention has the effect of inhibiting the lipase enzyme activity of the causative agent of seborrheic skin inflammation.
본 발명에 따른 조성물은 피부 세포에 악영향을 미치지 않은 안전성을 가지면서 지루성 두피 염증 원인균에 의해 악화된 두피 상태를 개선시키므로 화장품, 퍼스널 케어 제품, 의약품 등으로 활용될 수 있다.The composition according to the present invention improves the scalp condition deteriorated by seborrheic scalp inflammation-causing bacteria while having safety without adversely affecting skin cells, so it can be used as cosmetics, personal care products, pharmaceuticals, and the like.
이하 본 발명을 보다 구체적으로 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 목적을 달성하기 위하여 본 발명은 가래(Potamogeton distincutus) 추출물을 유효성분으로 함유하는 지루성 피부 염증 개선용 피부 외용제 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a composition for topical skin application for improving seborrheic skin inflammation containing an extract of Potamogeton distincutus as an active ingredient.
상기 가래는 연못이나 논에서 자라는 식물로서 물 위로 나오는 꽃과 물에 잠기는 잎, 물 위에 뜨는 잎으로 구성된다. 열매는 수과인데 딱딱하고 등 부분이 좁은 날개가 있다. 가래나무 열매도 가래라고 하나 본 식물과 다른 것으로 구별된다. 상기 가래 추출물은 꽃, 잎 또는 뿌리 어느 것이나 다 사용가능하다.The sputum is a plant that grows in a pond or rice field, and is composed of flowers coming out of the water, leaves submerged in water, and leaves floating on the water. The fruit is an achene, which is hard and has narrow wings on the back. The fruit of the sputum tree is also called sputum, but it is distinguished from the present plant. The sputum extract can be used for any of flowers, leaves or roots.
상기 가래 추출물은 상기 가래의 잎, 꽃, 열매, 줄기, 뿌리 및 종자로 이루어진 군으로부터 선택된 1종 이상의 추출물일 수 있으며, 전초를 사용할 수 있다.The sputum extract may be one or more extracts selected from the group consisting of leaves, flowers, fruits, stems, roots and seeds of the sputum, and an outpost may be used.
일 실시예에 의하면, 상기 피부가 두피인 것이 바람직하다. 본 발명에 따른 조성물이 사용될 수 있는 피부는 얼굴 피부, 손 피부, 신체 피부 등 다 가능하며, 바람직하게는 두피에 적용될 수 있다. According to one embodiment, it is preferable that the skin is the scalp. The skin to which the composition according to the present invention can be used may be face skin, hand skin, body skin, etc., and may be preferably applied to the scalp.
일 실시예에 의하면, 상기 가래 추출물의 함량은 조성물 총 중량에 대하여 0.001~10 중량%, 보다 바람직하게는 0.01~5중량%, 보다 더 바람직하게는 0.02~3중량%로 포함되는 것이 바람직하다. 상기 가래 추출물의 함량이 0.001중량% 보다 적게 포함되면, 지루성 피부염의 개선 효과가 미비하며, 10중량% 보다 많이 포함되면, 피부 자극 및 트러블이 생길 수 있다. According to one embodiment, the content of the sputum extract is preferably included in 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, and even more preferably 0.02 to 3% by weight based on the total weight of the composition. If the content of the sputum extract is less than 0.001% by weight, the improvement effect of seborrheic dermatitis is insignificant, and if it is included more than 10% by weight, skin irritation and trouble may occur.
상기 가래 추출물의 함량이 0.001 중량% 미만이면 유효한 효과를 나타낼 수 없으며, 10중량% 초과하면 변색, 변취 등 제형 안정성에 문제가 발생될 수 있다.If the content of the sputum extract is less than 0.001% by weight, an effective effect cannot be exhibited, and if it exceeds 10% by weight, problems with formulation stability such as discoloration and odor may occur.
일 실시예에 의하면, 상기 조성물은 지루성 피부 또는 두피 염증 원인균에 의한 피지 과다 생성을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다. 지루성 피부염의 개선에는 여러가지 방법이 있으나, 본 발명에서는 지루성 피부 염증 원인균의 피지 과다 생성을 억제하는 방법으로 사용되는 것이 바람직하다. According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by suppressing excessive production of sebum by a causative agent of seborrheic skin or scalp inflammation. There are various methods for improving seborrheic dermatitis, but in the present invention, it is preferable to use a method for suppressing excessive sebum production of seborrheic skin inflammation-causing bacteria.
일 실시예에 의하면, 상기 조성물은 지루성 두피 염증 원인균에 의한 염증성 사이토카인 발현 촉진을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다.According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by suppressing the promotion of inflammatory cytokine expression by the causative bacteria of seborrheic scalp inflammation.
일 실시예에 의하면, 상기 조성물은 지루성 두피 염증 원인균의 리파아제 효소 활성을 억제하여 지루성 두피 염증을 개선하는 것이 바람직하다.According to one embodiment, it is preferable that the composition improves seborrheic scalp inflammation by inhibiting the lipase enzyme activity of the causative agent of seborrheic scalp inflammation.
일 실시예에 의하면, 상기 지루성 두피 염증 원인균은 Malassezia globosa와 Malassezia restricta인 것이 바람직하다.According to one embodiment, the causative bacteria of seborrheic scalp inflammation are preferably Malassezia globosa and Malassezia restricta .
상기“추출물"은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 천연물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 것이며 또한 천연물의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함하는 광범위한 개념이며, 구체적으로 상기 가공 또는 처리는 추출물을 추가적으로 발효, 또는 효소처리 하는 것일 수 있다. 따라서 본 명세서에서 추출물은 발효물, 농축물, 건조물을 포함하는 광범위한 개념이며, 구체적으로 본 명세서에서 추출물은 물 또는 유기 용매의 추출물일 수 있다.The “extract” includes all substances obtained by extracting the components of natural substances, regardless of the extraction method, extraction solvent, extracted component or extract form, and also extracts the substances obtained by extracting the components of natural substances and then extracts them by other methods. It is a broad concept that includes all materials that can be obtained by processing or processing, and specifically, the processing or processing may be additionally fermenting or enzymatically treating the extract. It is a broad concept including, specifically, in the present specification, the extract may be an extract of water or an organic solvent.
본 발명의 일 실시예에서, 추출은 열수 추출, 에탄올 추출, 가열 추출, 냉침 추출, 환류 추출, 환류냉각 추출, 또는 초음파 추출 등이 이용될 수 있으며, 통상의 기술자에게 알려진 추출법이라면 제한이 없으며, 열수 추출, 에탄올 추출 들이 사용될 수 있다. In one embodiment of the present invention, hot water extraction, ethanol extraction, heat extraction, cold extraction, reflux extraction, reflux cooling extraction, or ultrasonic extraction may be used for extraction, and any extraction method known to those skilled in the art is not limited, Hot water extraction, ethanol extraction can be used.
본 발명의 일 측면에 있어서, 추출은 실온에서 수행할 수도 있으나, 보다 효율적인 추출을 위해서는 가온 조건 하에서 수행할 수 있으며, 바람직하게는 약 40 내지 100℃, 더욱 바람직하게는 약 80℃의 온도에서 추출할 수 있으나, 이에 한정되는 것은 아니다. 추출시간은 약 2 내지 약 14시간, 구체적으로는 8시간 내지 14시간, 더욱 구체적으로는 11시간 내지 13시간, 가장 구체적으로는 12시간 동안 수행할 수 있으나 이에 한정되는 것은 아니며, 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 상기 추출은 활성성분을 보다 다량 수득하기 위해 1 회 이상 여러 번 추출할 수 있으며, 바람직하게는 1 내지 5회, 더욱 바람직하게는 3회 연속추출하여 합한 추출액을 이용할 수 있다.In one aspect of the present invention, extraction may be performed at room temperature, but for more efficient extraction, it may be performed under heated conditions, preferably at about 40 to 100 ° C., more preferably at about 80 ° C. It can be done, but is not limited thereto. The extraction time may be about 2 to about 14 hours, specifically 8 to 14 hours, more specifically 11 to 13 hours, and most specifically 12 hours, but is not limited thereto, and the extraction solvent and extraction It may vary depending on conditions such as temperature. The extraction may be performed one or more times in order to obtain a larger amount of the active ingredient, preferably 1 to 5 times, more preferably 3 consecutive times, and combined extracts may be used.
구체적으로는 상기 추출물은 물, 유기 용매 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상의 추출물인 것이 바람직하다. 예를 들면, 추출 용매로는 정제수, 탄소수 1 내지 15의 알코올, 케톤, 에테르, 아로마틱 링 화합물 등을 들 수 있다.Specifically, the extract is preferably one or more extracts selected from the group consisting of water, organic solvents, and mixtures thereof. For example, the extraction solvent includes purified water, alcohol having 1 to 15 carbon atoms, ketones, ethers, aromatic ring compounds, and the like.
상기 추출물은 가래를 잘 씻어 건조한 뒤, 물, 유기용매 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상의 추출물인 것이 바람직하다. 상기 유기용매는 탄소수 1 내지 10의 무수 또는 함유 메탄올, 에탄올, 프로필알코올, 부틸알코올, 글리세린, 프로필렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 1종 이상일 수 있다.The extract is preferably one or more extracts selected from the group consisting of water, organic solvents, and mixtures thereof after washing and drying the sputum well. The organic solvent may be at least one selected from the group consisting of methanol, ethanol, propyl alcohol, butyl alcohol, glycerin, propylene glycol, and butylene glycol having 1 to 10 carbon atoms.
상기 추출물 또는 그 추출물의 가용성 분획물은 그대로 사용할 수도 있으나, 여과 후 농축하여 엑기스 형태로 사용할 수 있으며, 농축 후 건조물의 형태로 사용할 수도 있다.The extract or a soluble fraction of the extract may be used as it is, but may be used in the form of an extract after being concentrated after filtration, or may be used in the form of a dried product after being concentrated.
일 실시예에 의하면, 건조는 증발 건조, 분무 건조, 동결 건조일 수 있으며 구체적으로 동결 건조 시에는 -50 내지 -70℃에서 3~4일 동안 동결 건조를 수행할 수 있다. According to one embodiment, drying may be evaporation drying, spray drying, freeze drying, and specifically, freeze drying may be performed at -50 to -70 ° C for 3 to 4 days during freeze drying.
일 실시예에 의하면, 상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 로션, 파우더, 비누, 계면활성제 함유 클린싱 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 샴푸, 린스, 토닉 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것이 바람직하다.According to one embodiment, the composition is a group consisting of solutions, suspensions, emulsions, pastes, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations, shampoos, rinses, tonics and sprays It is preferred to have a formulation selected from
본 발명의 일 측면에 따른 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition according to one aspect of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc as a carrier component Alternatively, zinc oxide or the like may be used.
본 발명의 일 측면에 따른 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition according to one aspect of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additionally propellants such as chlorofluorohydrocarbons, propane/butane or dimethyl ether.
본 발명의 일 측면에 따른 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition according to one aspect of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 일 측면에 따른 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition according to one aspect of the present invention is a suspension, water, a liquid diluent such as ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester and The same suspending agent, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like can be used.
본 발명의 일 측면에 따른 화장료 조성물의 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산에스테르 등이 이용될 수 있다.In the case of surfactant-containing cleansing of the cosmetic composition according to one aspect of the present invention, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarco Cinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
본 발명의 일 측면에 따른 화장료 조성물에는 가래 추출물 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition according to one aspect of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the sputum extract. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts.
본 발명의 일 측면에 있어서, 화장료 조성물에는 또한, 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합해도 된다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In one aspect of the present invention, the cosmetic composition may further contain components included in general cosmetic compositions as necessary in addition to the above functional additives. Ingredients other than those included include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation accelerators, cooling agents, antiperspirants, purified water and the like.
상기 피부 외용제는 피부 외부에서 도포되는 어떠한 것이라도 포함될 수 있는 총칭이며, 다양한 제형의 화장료가 여기에 포함될 수 있다.The external skin preparation is a general term that may include anything applied to the outside of the skin, and cosmetics of various formulations may be included here.
일 실시예에 의하면, 상기 피부 외용제 조성물이 두피 상태 개선용 화장료 조성물인 것이 바람직하다.According to one embodiment, it is preferable that the composition for external application for skin is a cosmetic composition for improving scalp conditions.
일 실시예에 의하면, 상기 피부 외용제 조성물이 두피 상태 개선용 의약외품 조성물인 것이 바람직하다.According to one embodiment, it is preferable that the composition for external application for skin is a quasi-drug composition for improving scalp conditions.
본 발명의 일 측면에 따른 약학 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 연질 또는 경질 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결 건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기The pharmaceutical composition according to one aspect of the present invention may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, and sucrose in one or more compounds. Alternatively, it is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. suppositories
제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.As the zero, witepsol, macrogol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.
본 발명의 일 측면에 있어서, 조성물의 약학적 투여 형태는 이들의 약학적으로 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.In one aspect of the present invention, the pharmaceutical dosage form of the composition may be used in the form of a pharmaceutically acceptable salt thereof, and may also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
상기 염으로는 약학적으로 허용되는 것이면 특별히 한정되지 않으며, 예를 들어 염산, 황산, 질산, 인산, 불화수소산, 브롬화수소산, 포름산 아세트산, 타르타르산, 젖산, 시트르산, 푸마르산, 말레산, 숙신산, 메탄술폰산, 벤젠술폰산, 톨루엔술폰산, 나프탈렌술폰산 등을 사용할 수 있다.The salt is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, and methanesulfonic acid. , benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and the like can be used.
본 발명의 일 측면에 있어서, 조성물은 목적하는 바에 따라 비경구 투여하거나 경구 투여할 수 있으며, 하루에 체중 1 ㎏당 0.1~500 ㎎, 바람직하게는 1~100 ㎎의 양으로 투여되도록 1 내지 수회에 나누어 투여할 수 있다.In one aspect of the present invention, the composition can be administered parenterally or orally as desired, and is administered in an amount of 0.1 to 500 mg per 1 kg of body weight per day, preferably 1 to 100 mg, 1 to several times. It can be divided into doses.
특정 환자에 대한 투여용량은 환자의 체중, 연령, 성별, 건강 상태, 식이, 투여 시간, 투여 방법, 배설률, 질환의 중증도 등에 따라 변화될 수 있다.The dosage for a specific patient may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of the disease, and the like.
본 발명의 일 측면에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 연질 또는 경질 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 피부 외용제, 좌제, 주사제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 제형화하여 사용될 수 있으며, 바람직하게는 주사제 또는 피부 외용제의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition according to one aspect of the present invention, according to a conventional method, oral formulations such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, aerosols, external skin preparations such as ointments and creams, It may be formulated and used in any form suitable for pharmaceutical preparations, including suppositories, injections, and sterile injection solutions, etc., and may be preferably formulated and used in the form of injections or external skin preparations.
본 발명의 일 측면에 따른 조성물은, 쥐, 생쥐, 가축, 인간 등의 포유동물에 비경구, 경구 등의 다양한 경로로 투여될 수 있으며, 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 경피(trandermally), 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다.The composition according to one aspect of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes such as parenteral and oral, and all methods of administration can be expected, for example, It can be administered orally, transdermally, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebroventricular injection.
본 발명의 일 측면에 있어서, 식품 조성물은 건강기능식품 조성물일 수 있다. 본 발명의 일 측면에 따른 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 분말제, 드링크제와 같은 액제, 캐러멜, 겔, 바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.In one aspect of the present invention, the food composition may be a health functional food composition. The formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquids such as drinks, caramels, gels, bars, and the like. The food composition of each formulation can be selected and blended without difficulty by those skilled in the art according to the formulation or purpose of use other than the active ingredient, and synergistic effects can occur when applied simultaneously with other ingredients.
본 발명의 일 측면에 따른 식품 조성물에 있어서, 상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 5000mg/kg/일, 보다 구체적으로는 50 mg/kg/일 내지 500mg/kg/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등 다양한 요인에 따라 달라질 수 있다.In the food composition according to one aspect of the present invention, the dosage determination of the active ingredient is within the level of those skilled in the art, and its daily dosage is, for example, 0.1 mg/kg/day to 5000 mg/kg/day, more specifically It may be 50 mg/kg/day to 500 mg/kg/day, but is not limited thereto, and may vary depending on various factors such as the age, health condition, and complications of the subject to be administered.
본 발명의 일 측면에 따른 식품 조성물은, 예를 들어, 츄잉껌, 캐러멜 제품, 캔디류, 빙과류, 과자류 등의 각종 식품류, 청량 음료, 미네랄 워터, 알코올 음료 등의 음료 제품, 비타민이나 미네랄 등을 포함한 건강기능성 식품류일 수 있다.The food composition according to one aspect of the present invention is, for example, various foods such as chewing gum, caramel products, candies, frozen confectionery, and confectionery, beverage products such as soft drinks, mineral water, and alcoholic beverages, and health products including vitamins and minerals. It may be functional foods.
상기 외에 본 발명의 일 측면에 있어서, 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 일 측면에 있어서, 기능성 식품 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 일 측면에 있어서, 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 포함되는 것이 일반적이다.In addition to the above, in one aspect of the present invention, the food composition is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. In addition, in one aspect of the present invention, functional food compositions may include natural fruit juice, fruit juice beverages, and fruit flesh for preparing vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not so critical, but in one aspect of the present invention, it is generally included in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition.
이하, 실시예 및 시험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 실시예 및 시험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 하기예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail with examples and test examples. However, these examples and test examples are provided only for illustrative purposes to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.
상기 가래 추출믈은 상기 가래의 잎, 꽃, 열매, 줄기, 뿌리 및 종자로 이루어진 군으로부터 선택된 1종 이상의 추출물일 수 있으며, 전초를 사용할 수 있다.The sputum extract may be one or more extracts selected from the group consisting of leaves, flowers, fruits, stems, roots and seeds of the sputum, and an outpost may be used.
[제조예][Production Example] 가래 추출물 제조Preparation of sputum extract
가래 전초 100g을 수거하여 70% 에탄올 수용액 5 L를 넣고 실온에서 48시간 냉침한 후 여과 및 감압 농축하여 추출물 15 g을 얻었다. 세포 실험을 진행하기 위해 추출물을 Dimethyl sulfoxide (DMSO)에 녹여 시료를 제조하였다.100 g of sputum sheath was collected, put in 5 L of 70% ethanol aqueous solution, cooled at room temperature for 48 hours, filtered, and concentrated under reduced pressure to obtain 15 g of extract. To conduct cell experiments, samples were prepared by dissolving the extract in dimethyl sulfoxide (DMSO).
실험예 1 인간 피지선 세포 및 피부 각질 형성 세포 배양 조건 Experimental Example 1 Human sebaceous gland cells and skin keratinocyte culture conditions
인간 피지선 세포(Human Sebocyte)는 Celprogen (USA)에서 구입하여 사용하였다. 배양 배지는 Human sebocyte complete media with serum (M36079-01S, Celprogen, USA) 배지를 사용하여 37℃, 5% CO2 조건에서 배양하였다. Human sebocytes were purchased from Celprogen (USA) and used. As the culture medium, Human sebocyte complete media with serum (M36079-01S, Celprogen, USA) was used and cultured at 37°C and 5% CO 2 conditions.
인간 피부 각질 형성 세포(Normal Human Epidermal Keratinocyte, NHEK)는 ATCC(USA)에서 구입하여 사용하였다. 배양 배지는 Keratinocyte growth kit (ATCC, USA)을 첨가한 Dermal cell basal medium (ATCC, USA) 배지를 사용하여 37℃, 5% CO2 조건에서 배양하였다. Normal Human Epidermal Keratinocyte (NHEK) was purchased from ATCC (USA) and used. As the culture medium, Dermal cell basal medium (ATCC, USA) supplemented with Keratinocyte growth kit (ATCC, USA) was used and cultured at 37°C and 5% CO 2 conditions.
실험예 2 Experimental Example 2 Malassezia restrictaMalassezia restricta 및 and Malassezia globosaMalassezia globosa 배양 조건 culture conditions
실험에 사용된 Malassezia restricta (M.restricta, KCTC 27527)와 Malassezia globosa (M.globosa, KCTC 27535)는 한국생명공학연구원의 생물자원센터(KCTC)에서 분양 받았다. 배양 배지는 Leeming and Notman(LNA)를 사용하여 32 ℃ 조건에서 배양하고, 3일에 한번씩 계대 배양을 시행하였다. Malassezia restricta ( M.restricta , KCTC 27527) and Malassezia globosa ( M.globosa , KCTC 27535) used in the experiment were purchased from the Biological Resources Center (KCTC) of the Korea Research Institute of Bioscience and Biotechnology. The culture medium was cultured at 32 ° C using Leeming and Notman (LNA), and subculture was performed once every 3 days.
실험예 3 Experimental Example 3 MalasseziaMalassezia 효모균 배양액 처리를 통한 세포 실험 모델에서 지루성 두피 염증 환경 유도 Induction of seborrheic scalp inflammatory environment in cell experimental model through yeast culture solution treatment
지루성 두피염에서 많이 발견된다고 알려진 M.restricta (5X105)와 M.globosa (1X106)을 각각 20 ml LNA 배지에 접종 후 72시간 동안 배양하였다. 사전 실험을 통해 피지선 세포 증식 및 세포 내 피지 생성 촉진이 가장 많이 되는 배양액 비율 조건을 M.restricta 배양액 : M.globosa 배양액 = 9:1(세포 배양액에 2.5%(v/v) 처리)으로 확인하여 추후 시험에서 지루성 두피 염증 환경 유도제로 사용하였다. M.restricta (5X10 5 ) and M.globosa (1X10 6 ), which are known to be frequently found in seborrheic scalpitis, were each inoculated into 20 ml LNA medium and cultured for 72 hours. Through preliminary experiments, it was confirmed that the culture medium ratio conditions that promote sebaceous gland cell proliferation and intracellular sebum production the most were M.restricta culture medium : M.globosa culture medium = 9:1 (cell culture medium treated with 2.5% (v/v)). In subsequent tests, it was used as an inducer of seborrheic scalp inflammation environment.
실험예 4 Experimental Example 4 MalasseziaMalassezia 효모균으로 유도된 피지 과다 생성 억제 효과 Inhibitory effect on excessive sebum production induced by yeast
본 발명의 가래 추출물의 지루성 두피 염증 원인균에 의한 피지 과다 생성 억제 효과를 오일레드 오 (Oil Red O) 염색법으로 평가하였다. 피지선 세포를 1X105 cells/well 농도로 24웰 플레이트에 분주한 후 24시간 동안 배양하였다. 배양 배지를 제거 후 Human sebocyte serum free media(M36079-01, Celprogen, USA)에 실험예 3에서 설명한 것과 같이 Malassezia 효모균 배양액을 처리하여 피지 생성을 유도하였고, 가래 추출물을 농도 별로 동시 처리하여 피지 생성 억제 효과를 확인하였다. 피지 생성 억제 효과를 측정하기 위하여 보다 구체적으로 다음의 과정을 실행하였다. Malassezia 효모균 배양액과 가래 추출물을 48시간 동시 처리 후, PBS로 세척한 세포를 30분간 10% 포름알데이드 용액으로 고정하였다. 고정된 세포는 PBS로 2회, 50% 이소프로판올로 1회 세척하고, 0.4% 오일 레드 오 용액으로 45분간 염색하였다. 염색된 세포는 70% 에탄올로 1회, PBS로 2회 세척하였다. 세척 후 웰플레이트를 충분히 건조 시킨 후 100% 이소프로판올로 염색된 오일 레드 오 용액을 다시 녹여내어 micro-plate reader로 520 nm에서 흡광도를 측정하여 세포 내 생성된 중성 지방의 양을 정량하였다. The effect of the sputum extract of the present invention on inhibiting excessive sebum production by the causative agent of seborrheic scalp inflammation was evaluated by Oil Red O staining method. Sebaceous gland cells were seeded in a 24-well plate at a concentration of 1X10 5 cells/well and cultured for 24 hours. After removing the culture medium, sebum production was induced by treating Malassezia yeast culture medium in Human sebocyte serum free media (M36079-01, Celprogen, USA) as described in Experimental Example 3, and sebum production was inhibited by simultaneously treating sputum extracts by concentration The effect was confirmed. In order to measure the sebum production inhibitory effect, the following process was performed in more detail. After simultaneous treatment of Malassezia yeast culture medium and sputum extract for 48 hours, cells washed with PBS were fixed with a 10% formaldehyde solution for 30 minutes. The fixed cells were washed twice with PBS and once with 50% isopropanol, and stained with 0.4% Oil Red O solution for 45 minutes. Stained cells were washed once with 70% ethanol and twice with PBS. After washing and sufficiently drying the well plate, the oil red O solution stained with 100% isopropanol was dissolved again, and the absorbance was measured at 520 nm using a micro-plate reader to quantify the amount of neutral fat produced in the cells.
측정 결과는 하기 표 1에 나타내었다.The measurement results are shown in Table 1 below.
상기 표 1에 나타낸 바와 같이, Malassezia 효모균 배양액은 무처리 대조군과 LNA 배지 대조군에 비해 피지 생성을 확연히 유도시키며, 본 발명의 조성물에서 유효성분으로 사용되는 가래 추출물은 Malassezia 효모균 배양액으로 유도된 피지 생성을 효과적으로 억제시킴을 확인하였다. As shown in Table 1, the Malassezia yeast culture solution significantly induces sebum production compared to the untreated control and the LNA medium control, and the sputum extract used as an active ingredient in the composition of the present invention suppresses sebum production induced by the Malassezia yeast culture solution. It was confirmed that it inhibited effectively.
실험예 5 Experimental Example 5 MalasseziaMalassezia 효모균으로 유도된 인간 피지선 세포와 피부 각질 형성 세포에서의 염증성 사이토카인 발현 억제 효과 Inhibitory effect of inflammatory cytokine expression in yeast-derived human sebaceous gland cells and skin keratinocytes
본 발명의 가래 추출물의 Malassezia 효모균 배양액으로 유도된 지루성 두피 염증 억제 효과를 인간 피지선 세포와 피부 각질 형성 세포에서 염증성 사이토카인 발현 측정을 통해 평가하였다. 실험예 3에서 설명한 것과 같이 Malassezia 효모균 배양액을 처리하여 지루성 두피 염증을 유도하였고, 가래 추출물 100 ppm을 24시간 동시처리 하였다. 24시간 후, 각 세포 배양액에 발현되어 나온 염증성 사이토카인 (IL-1α, IL-6, IFN-γ)을 ELISA kit를 통해 세포 배양액 내 발현량을 측정하였다. ELISA는 Rnd systems (IL-1α: DY200-05 / IL-6: DY206-05 / IFN-γ: DY285B-05)을 사용하였고, 제조사의 권장 방법에 따라 실험을 실시하였다.The inhibitory effect of the seborrheic scalp inflammation induced by the Malassezia yeast culture medium of the sputum extract of the present invention was evaluated by measuring the expression of inflammatory cytokines in human sebaceous gland cells and skin keratinocytes. As described in Experimental Example 3, seborrheic scalp inflammation was induced by treating Malassezia yeast culture medium, and 100 ppm of sputum extract was simultaneously treated for 24 hours. After 24 hours, the expression level of inflammatory cytokines (IL-1α, IL-6, IFN-γ) expressed in each cell culture medium was measured in the cell culture medium through an ELISA kit. ELISA was performed using Rnd systems (IL-1α: DY200-05 / IL-6: DY206-05 / IFN-γ: DY285B-05) according to the manufacturer's recommended method.
측정 결과는 하기 표 2에 나타내었다.The measurement results are shown in Table 2 below.
(100 ppm)phlegm extract
(100 ppm)
(NHEK)human skin keratinocytes
(NHEK)
상기 표 2에 나타낸 바와 같이, Malassezia 효모균 배양액은 인간 피부 각질 형성 세포와 피지선 세포의 염증성 사이토카인의 발현을 증가시킴으로써 염증 반응을 유도시키는 것을 확인하였다. 본 발명의 가래 추출물은 각 세포에서 발현된 염증성 사이토카인의 발현을 효과적으로 억제시킴을 확인하여 지루성 두피 염증을 진정시키는 효과가 있음을 알 수 있다.As shown in Table 2, it was confirmed that the Malassezia yeast culture medium induces an inflammatory response by increasing the expression of inflammatory cytokines in human skin keratinocytes and sebaceous gland cells. It can be seen that the sputum extract of the present invention has an effect of calming seborrheic scalp inflammation by confirming that it effectively inhibits the expression of inflammatory cytokines expressed in each cell.
실험예 6 Experimental Example 6 Malassezia globosaMalassezia globosa ( ( M.globosaM. globosa )의 리파아제 효소 활성 저해 효과) Lipase enzyme activity inhibitory effect
M.globosa가 분비하는 리파아제는 피지 구성물인 트리글리세라이드와 에스테르를 분해하여 피부 자극성의 불포화 지방산인 리놀레산과 올레산이 만들어진다. 가래 추출물의 M.globosa가 생성한 lipase 활성 저해 효과는 Lipase assay(Lipolytic enzyme activity)를 통해 평가하였고, 구체적으로 다음의 과정을 실행하였다. M.globosa 배양액 100 μl에 90 mM Citrate buffer 30 μl, 10 mM p-NPD(4-Nitrophenyl dodecanoate) 30 μl, 5% Triton X-100 30 μl, Tris-HCl buffer(pH 8.0) 610 μl을 첨가하여 enzyme buffer을 준비하였다. Enzyme buffer에 양성대조군으로 Quercetin 100 μM과 농도 별 가래 추출물 100 μl를 첨가하여 30℃에서 1시간 반응시켰다. p-NPD가 p-nitrophenol로 가수분해 된 정도를 405 nM에서 흡광도 측정하였다. Lipase secreted by M. globosa breaks down triglycerides and esters, which are components of sebum, to produce linoleic acid and oleic acid, unsaturated fatty acids with skin irritation. The lipase activity inhibitory effect produced by M.globosa of the sputum extract was evaluated through Lipase assay (Lipolytic enzyme activity), and the following process was specifically performed. Add 30 μl of 90 mM citrate buffer, 30 μl of 10 mM p-NPD (4-Nitrophenyl dodecanoate), 30 μl of 5% Triton X-100, and 610 μl of Tris-HCl buffer (pH 8.0) to 100 μl of M.globosa culture medium. Enzyme buffer was prepared. As a positive control, 100 μM of Quercetin and 100 μl of sputum extract by concentration were added to the enzyme buffer and reacted at 30 ° C for 1 hour. The degree of hydrolysis of p-NPD to p-nitrophenol was measured by absorbance at 405 nM.
측정 결과는 하기 표 3에 나타내었다.The measurement results are shown in Table 3 below.
상기 표 3에 나타낸 바와 같이, M. globosa가 생성한 리파아제 효소 활성을 가래 추출물이 효과적으로 억제시킴을 확인하여 지루성 두피염의 원인이 되는 피부 자극성 불포화 지방산의 생성 억제에 효과가 있음을 알 수 있다.As shown in Table 3, it was confirmed that the sputum extract effectively inhibited the lipase enzyme activity produced by M. globosa , indicating that it was effective in inhibiting the production of skin-irritating unsaturated fatty acids that cause seborrheic scalpitis.
제형예formulation example
하기에 본 발명의 가래 추출물을 포함하는 각종 두피 적용 조성물 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, various examples of scalp application compositions containing the sputum extract of the present invention will be described, but the present invention is not intended to limit them, but only to be specifically described.
Claims (12)
상기 피부가 두피인 것을 특징으로 하는 피부 외용제 조성물.According to claim 1,
A composition for external application for skin, characterized in that the skin is a scalp.
상기 가래 추출물의 함량은 조성물 총 중량에 대하여 0.001~10 중량%로 포함되는 것을 특징으로 하는 피부 외용제 조성물.According to claim 1,
The content of the phlegm extract is a composition for external application for skin, characterized in that contained in 0.001 to 10% by weight relative to the total weight of the composition.
상기 조성물은 지루성 두피 염증 원인균에 의한 피지 과다 생성을 억제하는 것을 특징으로 하는 피부 외용제 조성물.According to claim 1
The composition for external application for skin, characterized in that the composition suppresses the excessive production of sebum by the causative agent of seborrheic scalp inflammation.
상기 조성물은 지루성 두피 염증 원인균에 의한 염증성 사이토카인 발현 촉진을 억제하는 것을 특징으로 하는 피부 외용제 조성물.According to claim 1
The composition for external application for skin, characterized in that for suppressing the promotion of inflammatory cytokine expression by the causative agent of seborrheic scalp inflammation.
상기 조성물은 지루성 두피 염증 원인균의 리파아제 효소 활성을 억제하는 것을 특징으로 하는 피부 외용제 조성물.According to claim 1
The composition for external application for skin, characterized in that the composition inhibits the lipase enzyme activity of the causative agent of seborrheic scalp inflammation.
상기 지루성 두피 염증 원인균은 Malassezia globosa와 Malassezia restricta인 것을 특징으로 하는 피부 외용제 조성물.According to claim 5,
The seborrheic scalp inflammation causative bacteria are Malassezia globosa and Malassezia restricta composition for external application for skin, characterized in that.
상기 추출물은 물, 유기 용매 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상의 추출물인 것을 특징으로 하는 피부 외용제 조성물.According to claim 1
The extract is an external composition for skin, characterized in that at least one extract selected from the group consisting of water, organic solvents and mixtures thereof.
상기 유기 용매는 탄소수 1 내지 10의 무수 또는 함유 메탄올, 에탄올, 프로필알코올, 부틸알코올, 글리세린, 프로필렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는 피부 외용제 조성물.According to claim 8,
The organic solvent is an external composition for skin, characterized in that at least one selected from the group consisting of methanol, ethanol, propyl alcohol, butyl alcohol, glycerin, propylene glycol and butylene glycol having 1 to 10 carbon atoms.
상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 로션, 파우더, 비누, 계면활성제 함유 클린싱 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 샴푸, 린스, 토닉 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는 피부 외용제 조성물.According to claim 1
The composition has a formulation selected from the group consisting of solutions, suspensions, emulsions, pastes, lotions, powders, soaps, surfactant-containing cleansing oils, powder foundations, emulsion foundations, wax foundations, shampoos, rinses, tonics and sprays. A composition for external application for skin, characterized in that.
상기 피부 외용제 조성물이 두피 상태 개선용 화장료 조성물인 것을 특징으로 하는, 피부 외용제 조성물.According to any one of claims 1 to 10,
The composition for external application for skin, characterized in that the composition for external application for skin is a cosmetic composition for improving scalp conditions.
상기 피부 외용제 조성물이 두피 상태 개선용 의약외품 조성물인 것을 특징으로 하는, 피부 외용제 조성물.According to any one of claims 1 to 10,
The composition for external application for skin, characterized in that the composition for external application for skin is a quasi-drug composition for improving scalp condition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210077546A KR20220168036A (en) | 2021-06-15 | 2021-06-15 | Skin external application composition for improving seborrheic dematitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210077546A KR20220168036A (en) | 2021-06-15 | 2021-06-15 | Skin external application composition for improving seborrheic dematitis |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220168036A true KR20220168036A (en) | 2022-12-22 |
Family
ID=84578225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210077546A KR20220168036A (en) | 2021-06-15 | 2021-06-15 | Skin external application composition for improving seborrheic dematitis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220168036A (en) |
-
2021
- 2021-06-15 KR KR1020210077546A patent/KR20220168036A/en active Search and Examination
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100924920B1 (en) | Composition for preventing and curing acne | |
KR101017709B1 (en) | Cosmetic composition comprising the herbal mixed extract comprising panax ginseng c.a meyer showing hair-growth stimulating activity and preventing activity from hair loss | |
KR101957849B1 (en) | Composition for promoting hair growth or restoration and anti-inflammatory composition | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR102070789B1 (en) | Composition for ameliorating or treating acne comprising Salvia plebeia extract and its fraction as effective component | |
KR101347910B1 (en) | a Food Composition, a Cosmetic Composition, a Pharmaceutical Composition Comprising Supercritical Fluid Extract of Ginger and Extract of Dropwort Fermented | |
US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR20200054151A (en) | Composition for improving skin | |
KR20160040968A (en) | Cmposition for preventing hair loss or accelerating hair growth comprising scutellaria alpina extract | |
KR20220168036A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20210117247A (en) | Composition for improving skin comprising stevioside as active ingredient | |
KR20220168039A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20220168037A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20220168040A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20220168041A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20220168038A (en) | Skin external application composition for improving seborrheic dematitis | |
KR20170025363A (en) | Composition for improving skin | |
KR102564361B1 (en) | Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 | |
KR20150144688A (en) | Composition for improving scalp condition comprising extract of passiflora incarnate | |
KR101872919B1 (en) | Composition for improving skin | |
KR102262362B1 (en) | Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem | |
KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
KR102316957B1 (en) | Composition for preventing hair loss and enhancement of hair growth comprising pterosin compounds or derivative thereof | |
KR20170025356A (en) | Composition for improving skin | |
KR20230071880A (en) | Composition for preventing, improving or treating hair loss symptoms comprising Tambit1ho peel extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination |